Abstract: SA-PO263
Soluble Klotho Modifies the Mortality Risk Associated with Hypomagnesemia in Patients with Hemodialysis
Session Information
- Bone and Mineral Metabolism: Calcium, Magnesium, Kidney Stones
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 402 Bone and Mineral Metabolism: Clinical
Authors
- Nakashima, Akio, The Jikei University School of Medicine, Tokyo, Japan
- Ohkido, Ichiro, Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
- Yokoyama, Keitaro, Harumi Toriton Clinic of The Jikei University Hospital, Tokyo, Japan
- Yokoo, Takashi, The Jikei University School of Medicine, Tokyo, Japan
Background
Hypomagnesemia have been regarded as a risk factor of cardiovascular disease in patients with CKD. In vitro studies reported that hypomagnesemia induced downregulation of Klotho. We examined how soluble Klotho levels influence the association between serum magnesium levels and the risk of mortality in patients with hemodialysis.
Methods
This cohort study analyzed 1241 hemodialysis patients. We divided the study population into four groups based on serum soluble Klotho levels and magnesium levels. In this study, we defined the primary outcome was all-cause mortality. We used Cox proportional hazard model.
Results
Their mean age was 63.1 (±11,8) years, and median dialysis vintage was 84 (39 to 154) months. The distribution of Klotho levels was 325 (248 to 434) pg/ml. In addition, serum magnesium levels is 2.6 (± 0.46)mg/dl. During following period, 228 patients dead. Patients with lower magnesium (< 2.6mg/dl) and lower Klotho (325 pg/ml) were higher mortality than patients with higher magnesium and higher Klotho (HR 2.33,95%CI 1.37-3.97).
Conclusion
In this study, we found that lower magnesium and lower soluble Klotho is high risk of mortality in patients with hemodialysis.